基于图书统计分析,绘制有关甲胺在癌症中的当前研究情景的地图
Yuan Wang1, Sike He1, Ziqi Li1
1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Discover oncology
|August 11, 2025
概括
甲胺显示出潜在的抗癌作用,影响TP53等基因和AMPK/mTOR.等途径. 这项研究绘制了它在乳腺癌和结直肠癌中的相关性,有助于未来的研究.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 甲胺是2型糖尿病的主要治疗方法.
- 越来越多的证据表明甲胺具有抗癌性质.
- 现有的研究是分散的,阻碍了对甲胺在癌症中的作用的统一理解.
研究的目的:
- 系统地绘制梅特福林和癌症的研究格局.
- 揭示甲胺在不同癌症类型中的分子机制和治疗相关性.
- 为未来的癌症研究提供一个综合的视角.
主要方法:
- 图书识别分析框架.图书识别分析框架.
- 生物信息学分析.
- 系统地绘制研究文献的地图.
主要成果:
- 确定了关键的基因标:TP53,SIRT1和HIF1A.
- 突出显著的信号通路:AMPK/mTOR和p53.
- 揭示了与乳腺癌和结直肠癌的频繁联系.
结论:
- 甲胺的抗癌潜力得到了确定分子点和途径的支持.
- 这项研究提供了对甲在各种癌症中的作用的统一概述.
- 这些发现可以指导未来对基于甲胺的癌症治疗的研究.
相关概念视频
Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Mouse Models of Cancer Study
5.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K


